基于卷积神经网络的数据可解释框架用于阿尔茨海默氏症治疗计划
Sazia Parvin1, Sonia Farhana Nimmy2, Md Sarwar Kamal3
1Information Technology, Melbourne Polytechnic, Melbourne, VIC 3072, Australia. saziap@gmail.com.
Visual computing for industry, biomedicine, and art
|January 31, 2024
概括
这项研究引入了使用多式联络数据检测阿尔茨海默病 (AD) 的新框架. 该方法整合了机器学习和可解释的AI,以提高诊断AD的准确性和可解释性.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经系统疾病,患病率不断增加,诊断进展有限.
- 目前的AD检测方法通常依赖于单一的数据类型,阻碍了全面的分析.
- 机器学习 (ML) 和人工智能 (AI) 显示出改善AD诊断的希望.
研究的目的:
- 开发和评估使用多式联络数据对阿尔茨海默病 (AD) 分类的新框架.
- 整合可解释的AI (XAI) 技术来解释AD预测结果.
- 为了提高医疗专业人员对AD诊断的理解和解释性.
主要方法:
- 开发了一个框架,利用多模式数据,包括表格数据,磁共振成像 (MRI) 和遗传信息.
- 从表格数据和MRI图像中生成知识图,使用图形神经网络和基于区域的卷积神经网络 (CNN).
- 可解释性AI (XAI) 技术,包括层级相关性传播 (LRP) 和亚模块选择 (SP),用于模型解释性,以及用于遗传分析的图形基因树.
主要成果:
- 开发的框架成功地使用多式联络数据源的组合对阿尔茨海默病 (AD) 进行了分类.
- 可解释的人工智能 (XAI) 技术提供了从成像和表格数据中预测结果的见解.
- 一个图形基因树确定了与阿尔茨海默病相关的关键基因,有助于基因分析.
结论:
- 多模式数据集成与先进的ML/AI技术相结合,为准确的阿尔茨海默病 (AD) 检测提供了强大的方法.
- 纳入XAI提高了AI驱动的AD诊断工具的透明度和临床实用性.
- 该框架为推进阿尔茨海默病的研究和诊断提供了全面和可解释的解决方案.
更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.3K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
